7.3 Staff Investigators Within the UCSF Helen Diller Family Comprehensive Cancer Center are investigators who perform key roles in the activities of the Center, but are not specifically represented in our senior leader or programmatic line-up. Our Staff Investigators make sure that we, as a Center, are at the cutting edge of specific research areas that we believe will be important growth areas and opportunities in the future. Staff Investigators attend our quarterly off-site retreats, and report to the other members ofthe Center's leadership on new developments in these areas. In this application, we propose five of these individuals for funding: Celia Kaplan, Ph.D., Coordinator, Inreach Dr. Kaplan's research is in the field of health disparities and cancer prevention and control, as well as in conducting epidemiologic, health services, and communication research, with an emphasis on cancer care disparities. Her work has focused on assessing individual, community, and system factors associated with health access, and in factors affecting participation in clinical trials among patients, physicians, and community organizations. This expertise has led to the work she initiated, and will pursue as Staff Investigator. Dr. Kaplan partnered with Dr. Eric Small, Deputy Director and Associate Director of Clinical Sciences and of the Investigational Trials Resource (ITR), to evaluate the patterns of accrual to clinical trials at the Center. Overall accrual of minority and underserved populations (relative to the distribution of new cases seen at the Center, and relative to several catchment areas), and the relative contributions of outreach and inreach were evaluated. The results from this work led to the decision to specifically build an inreach effort in the Center. Dr. Kaplan will direct this initiative as part of her role as a Staff Investigator. Dr. Kaplan has established a center-wide initiative entitled,

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA082103-14
Application #
8388395
Study Section
Subcommittee G - Education (NCI)
Project Start
1999-08-05
Project End
2017-05-31
Budget Start
2012-09-19
Budget End
2013-05-31
Support Year
14
Fiscal Year
2012
Total Cost
$35,793
Indirect Cost
$12,934
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Autry, Adam; Phillips, Joanna J; Maleschlijski, Stojan et al. (2017) Characterization of Metabolic, Diffusion, and Perfusion Properties in GBM: Contrast-Enhancing versus Non-Enhancing Tumor. Transl Oncol 10:895-903
Pekmezci, Melike; Rice, Terri; Molinaro, Annette M et al. (2017) Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathol 133:1001-1016
Maertens, Ophélia; McCurrach, Mila E; Braun, Benjamin S et al. (2017) A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies. Cancer Res 77:5706-5711
de Smith, Adam J; Kaur, Maneet; Gonseth, Semira et al. (2017) Correlates of Prenatal and Early-Life Tobacco Smoke Exposure and Frequency of Common Gene Deletions in Childhood Acute Lymphoblastic Leukemia. Cancer Res 77:1674-1683
Stieglitz, Elliot; Mazor, Tali; Olshen, Adam B et al. (2017) Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia. Nat Commun 8:2127
Bartlett, Thomas E; Müller, Sören; Diaz, Aaron (2017) Single-cell Co-expression Subnetwork Analysis. Sci Rep 7:15066
Martin, Thomas; Baz, Rachid; Benson, Don M et al. (2017) A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Blood 129:3294-3303
Zhang, Jie; Yao, Tsun-Wen; Hashizume, Rintaro et al. (2017) Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas. J Neurooncol 131:495-505
Li, Megan; Kroetz, Deanna L (2017) Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther :
Aggarwal, Rahul; Behr, Spencer C; Paris, Pamela L et al. (2017) Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer. Mol Cancer Res 15:1221-1229

Showing the most recent 10 out of 168 publications